DiscoverBeginner's Mind
Beginner's Mind
Claim Ownership

Beginner's Mind

Author: Christian Soschner

Subscribed: 0Played: 9


Conversations about Life Science, Science, Business, M&A, Technology, Pharma, and Philosophy. Do you want to stay updated? Leave your eMail -
28 Episodes
Let's sit down for a conversation about my favorite topic: Fundraising in the Life Science Industry.How is it to raise significant financing rounds during a pandemic when the research focus is not related to SARS-CoV-2?It is my pleasure to welcome Dr. Daniela Marino, CEO and Co-founder of Cutiss AG.Speaker:Christian Soschner ( Marino  ( Life Science Invest ( AG ( part of our Network:Subscribe here: the show (
In the last episodes, I have talked with investors and decision-makers of the pharmaceutical industry about the importance of having a vision and passion for the life science company.I want to explore this topic further and ask the life science entrepreneur Christof Goetz to chat with me about finding your vision and passion for your company.Christof is a Serial Entrepreneur with more than 20 years of experience managing complex business, software, and hardware development projects. MyMind is a life science company based in Vienna. MyMinds vision is to help people with neurological impairments to live towards their full brain potential with affordable and easy to use brain training and assessment technology. MyMind currently focuses on Autism Spectrum Disorders (ASD), whether comorbid with Attention Deficit Hyperactivity Disorder (ADHD), Intellectual Disability (low IQ), Epilepsy, and Anxiety. Subsequently, MyMind will extend to other neurological issues such as dementia or stroke recovery.Speaker:Christof Goetz ( Soschner ( Life Science Invest ( Mind GmbH ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
In this episode, I had the pleasure of talking with two Diagnostics Experts.Irina Korschinek, CEO of Ingenetix and Albert Missbichler, Business Angel specialized in Diagnostics.Do you want to know answers to all or one of the following questions?• What is a PCR test?• Why is it the gold standard for measuring SARS-Cov2 Infections?• What does a positive or negative test result say?• Why do false positives and false negatives exist. Shouldn`t the test have 100% accuracy?• Why do no yes or no answers exist to a viral infection?• What makes diagnostics so complex?Speaker:Albert Missbichler ( Soschner ( Korschinek ( Life Science Invest ( ( ( part of our Network:Subscribe here: the show (
Did you know that the successful pipeline of one of the most important pharmaceutical companies in the United States started in Europe, and scientists from Prague played a key role? Did you know that profound expertise in turning deep tech life science into a business, scale it, and go public in the US can be found in Prague since the late 80s of the previous century?If you want to know which US pharmaceutical companies pipeline started in Prague, then listen to this Episode Number 25. I am delighted to host an exceptional guest from one of the most beautiful cities in Europe. I will talk with Karel Kubias, from  i&i in Prague.Karel studied organic chemistry and photochemistry at TH Merseburg, Germany, and holds an MBA in Healthcare Management (Auburn University program).He gained his broad professional knowledge and skills during his 24 years in various management positions at multinational chemical and pharmaceutical company Merck KGaA. Between 2006 – 2015, Karel worked in executive positions – first as Managing Director of Merck spol. s r.o.. Prague and then as Regional sales director for the region EEMEA (Eastern Europe, Middle East & Africa) of Merck Millipore division, where he acquired further experience on the international level. He now supports i&i Prague as Director for Partnerships and Strategic Alliances.i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics, and Drug discovery. The company focuses on projects in the discovery, pre-seed, or seed phase, projects with excellent innovative potential, which will benefit from the project-launching experience and networking skills developed by IOCB Tech over the last decade. Furthermore, the financial support provided by i&i Prague should significantly increase the appeal and value of a project for further licensees and/ or investors.Speaker:Christian Soschner ( Kubias ( Life Science Invest ( Prague ( Tech ( ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
Listen to my inspiring conversation with Vassilis Ragoussis about initiatives that support young scientists to become Entrepreneurs. We dived deep into the entrepreneurial Life Science Eco-System in Oxford, Europe, and the United States.If you want to know what the Eco-System in Oxford is doing for young scientist entrepreneurs, this podcast is for you. Learn more about Oxford University Biotech Society and Oxford Foundry.Vassilis is an avid networker and a Ph.D. student at the University of Oxford studying Clinical Medicine. His research requires to analyze large amounts of next-generation sequencing data using bioinformatics and computational analysis. In addition, he critically and objectively assesses his findings, validating any discoveries with functional experiments. During his time at Boston University and Oxford University, he competed at the highest level of rowing, dedicating 30+ hours a week to training and competing, gaining a profound understanding and tremendous respect for teamwork, time management, and team leadership. He has a strong interest in venture capital, life science consulting, and medical device innovations.Speaker:Christian SoschnerVassilis RagoussisOrganizations:CS Life Science Invest ( FoundryOxford University Biotech SocietyUniversity of OxfordBe part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
Listen to my conversation with Nicolaj Højer Nielsen about the life of an early-stage investors in Europe.Nicolaj Højer Nielsen is a serial entrepreneur and business angel who has been building startups since 1999. He focuses on high potential startups and has co-founded and invested in thirteen companies, primarily within IT. He has experience securing funding from all possible sources – friends and family, business angels, VC funds, and public funds. His expertise is based on reviewing thousands of different investment opportunities, and he knows the fundraising process from both sides of the table.His latest venture is Copenhagen United, an investment fund focusing on providing capital and mentoring for early-stage software companies.Let`s chat with him about his view on the early-stage investment eco-system in Europe.Speaker:Christian SoschnerNicolaj Højer NielsenCompanies:CS Life Science Invest ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.Governments are doing what’s necessary to deal with the situation. More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions taken in the United States. I rarely read anything about the situation in Asia. Is life back to normal in Asia? How is the risk assessment of the novel Corona Virus in Asian countries?That‘s why I asked a colleague who lives in Shanghai and is one of the best experts in Life Science and Asia in the world. In this webinar/podcast recording, I will talk with Irénée Robins about these topics. Born in North-Eastern France in 1971, Irénée Robin has been living in China for almost 20 years. Married with three children, genuinely bicultural, he speaks, reads, and writes Mandarin fluently.After ten years in the financial services industry with the BNP Paribas group, Irénée started his life sciences career in 2003 by joining Shanghai Cathay Biotech, where he established his first Sino-foreign joint venture with a major German specialty chemicals conglomerate,leading to the creation of Degussa Cathay Biotechnology in Jining, Shandong Province.From 2006 to 2011, he worked with the Institut Pasteur of Shanghai, an international research venture established by the Chinese Academy of Sciences, the Shanghai municipal government, and Institut Pasteur. Under his tenure, the institute grew from 40 to 240 researchers, with numerous drug/vaccine discovery programs against life-threatening infectious diseases such as HFMD, HCV, and malaria. His efforts were directed at increasing the institute’s financial resources, notably via expanding CSR programs with multinational corporations and successfully applying to European and international grants.In 2012, as a Senior Representative for the Biotechnology Innovation Organization (BIO), he organized the “BIO Convention in China” in Shanghai.From 2013 to early 2019, he was the Chief Marketing Officer  for Shanghai Newsummit Biopharma, a subsidiary of Shenzhen-listed Zhejiang Yatai Pharmaceuticals (SHE:002370). During those six years, he attracted more than 30 Western companies onto the Chinese market through a vast array of transaction types, from in-licensing to co-development, distribution, and service agreements. He also established 4 Sino-foreign joint ventures in 4 different Chinese cities, including China’s most advanced molecular pathology and next-gen cancer diagnostics lab (Shanghai  German JV partner) and a first-in-class IVD development venture based on patients’ immune status markers, the use of NGS platforms, and targeted data mining/deep learning algorithms (Guangzhou – French JV partner).Speaker:Christian Soschner (énée Robin ( Life Science Invest ( Medical ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
Do you want to know how to approach Pharma?Do you want to learn what information is needed to partner a life science project with Pharma?And how long the process takes?Then this podcast is for you.Listen to the expertise of Natalia Novac, Director of Emerging Technologies and Innovation, Eli Lilly.Natalia has profound experience in strategy, corporate, and business development. She had leading roles at Merck and now Eli Lilly.Speaker:Christian Soschner ( Novac ( Lilly ( Life Science Invest ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.Speaker:Christian Soschner ( Llewellyn-Davies ( Biologics ( Life Science Invest ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
Since the beginning of the SARS-CoV-2 Pandemic, more and more people got interested in the Life Science Industry.Scientists worldwide have worked together for decades and centuries to solve the world's most severe health problems. In the last decades, a unique Eco-System of start-ups, investors, industrial partners, and public funding organizations evolved out of this search for finding cures against the world's most complex diseases.In this episode, you will hear:How important is building strong relationships?How does this Life Science Value Eco System function in 2020? How do companies, investors, and Start-Ups interact with each other?What roles does the player have?How do investors life look like?And how do Start-Ups approach investors?Speaker:Bruno Montanari ( Soschner ( Life Science Invest ( Life Sciences ( part of our Network:Subscribe here: LSG2G Partners Experts in Life ScienceSupport the show (
Rumour has it: It takes 10-15 years to bring a new therapy to the patients. Only 1% of all scientific ideas make it to the market - is another statistical fact.How do those people who made developing novel therapies their mission make money on their way?In this episode, I have the huge pleasure to chat with Thomas Schirrmann. He has profound experience in starting companies from scratch, walking through the ups and downs of Death Valley, and turn it into a commercial success.Listen to his insights in creating and developing life science companies.Speaker:Christian Soschner ( Schirrmann ( TherapeuticsCS Life Science Invest ( ( you want to learn more about life science?Subscribe to our newsletter: Caring for people’s health as a trusted partnerSupport the show (
How is it to start a company from scratch, found it and fund it in the US, and get customers like the US Air Force and the Department of Defence.In this episode, you will hear how Jessica Walsh, Founder, and CEO of RxBandz, one of the most successful women in life science in the world, did it.In this episode, listen to Jessica’s stories about how to get into life science out of necessity, how it is to find the right team and develop the team and the project at the same time.Speaker:Christian Soschner ( Walsh ( Life Science Invest ( ( you want to learn more about life science?Subscribe to our newsletter: Super-Sensitive and EasySupport the show (
We are the average of the five people we spent the most time with. Or are we the opposite?Listen in this podcast episode how Daria Tataj sees it. Daria is THE number one networking expert in Europe. Daria Tataj is a researcher, Ph.D., keynote speaker, author, and world expert on innovation networks.  After having reached more than 30.000 decision-makers around the world through her work helping companies, governments, and cities to foster innovation through the strategic use of networks, Daria has now decided to share her knowledge with you in one Program, the Network Thinking Training.She is also one of the founding board members of the European Institute of Innovation & Technology ( you want to get in touch with Daria? Join her next networking webinar: Offer:As a subscriber to this podcast you get a EUR 100,- discount. Passcode: LSG2GPartner and member get a 46% discount. Become a member and  send a mail to for further information Book:Get Darias book at Amazon: Soschner ( Tataj ( Life Science Invest ( Innovation ( you want to learn more about life science?Become a member of the LSG2G Network. Join today: - Let's get your podcast launched! Start for FREEThe LSG2G Partners Experts in Life ScienceDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show (
Everybody comes in touch with the life science industry. Hardly anybody knew about the challenges, and hardships scientists have to overcome to bring a product from the university-level to the market.Since the outbreak of SARS-CoV-2, more and more people are becoming interested in life science investments. And ask the question: How does that work?In this episode, I am talking with entrepreneurs and investors from the LSG2G network. How do life science investments work? What are investors looking at? Is the life science industry right for Business Angels? What does it take to bring a product to the market?All these questions I discussed with the keynote speaker and panelists.Speaker:Andreas Grassauer ( Woollard ( Soschner ( de Souza ( Lininger ( Núñez-Garcia ( Stockinger ( Ventures ( Life Science Invest ( Ventures ( ( Sciences ( Ventures ( Stock Exchange ( you want to learn more about life science?Join exclusive future webinars and member-only events: Become a member of the LSG2G Network. Join today: - Nature is our remedy Since 1909.Support the show (
The current pandemic shines a light on deep tech companies. Especially in life science. Did you ask yourself the question: What is necessary to bring a scientific idea from universities into companies and ultimately onto the market?In this episode, I am talking with Klara Brandstätter and Jasmin Gungör. They are responsible for training, financing, and connecting deep-tech scientists. What exactly they are doing, you will hear in this episode.Speaker:Christian Soschner ( Güngör ( Brandstätter ( Life Science Invest ( Summer School ( you enjoy the podcast?Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly during the recording. The questions will be featured in the podcast.Do you like this idea? Join today: the show (
How to bring a scientific life science idea to patients? Three key components are needed:1. World-class science2. World-class development team3. Massive public and private fundingIn this episode, I am talking with Michael Browne and Kimberly Cornfield on how to solve these three problems. Reach out to Kimberly and Michael if you want to access their top-notch science networks within Crowdhelix and UCL.Speaker:Christian Soschner ( Cornfield ( Browne (  ( Life Science Invest (  ( you enjoy the podcast?Become a member of the LSG2G Network and join the recording. You will get a special "member only" invitation. You will have the unique opportunity to talk with the speakers directly in the Q&A - and you will get featured in the podcast episode.Do you like this idea? Join today: the show (
The current pandemic SARS Cov 2 is shining a light on vaccine development. Since December 2019, the novel coronavirus is known amongst scientists. The virus is highly contagious. As a first measure, many governments all over the world have ordered a complete lockdown of the countries.Some politicians make reverting life back to normal dependent on the existence of medication and/or vaccine. How long does it take to develop a vaccine against this novel coronavirus?In this episode, the vaccine development expert Ericht Tauber, CEO, and founder of Themis Bioscience, explains what it takes to develop a novel vaccine and also gives an outlook on the timeline.It was a huge pleasure to be accompanied by Elisabeth Pfneisl,, during the recording of this interview.Speaker:Christian Soschner ( Pfneisl ( Tauber ( ( Life Science Invest ( BioScience ( you enjoy the podcast?Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly in the Q&A. The questions will be featured in the podcast. Do you like this idea? Join today: the show (
#11: Digital Health

#11: Digital Health


Digital health is a technology that appeared only a few years ago. Up to now, it was very often overlooked. The current situation is helping digital health to show it's full potential. For example, Digital health can be used as a triage system, finding out first what kind of illness a patient has with chatbots and telemedicine solutions. Afterward, the patients can be referred to real-life doctors - to the right one.A solution Symptoma has developed. In this episode, I am talking with the CEO of Symptoma, Jama Nateqi, about the real potential of digital health.Another novel technology appeared recently - blockchain. Astrid Woollard, Partner at Scytale Ventures, is investing in companies that develop blockchain-based solutions. She has joined us to chat about the leverage blockchain can provide for digital health and the entire healthcare system. Speaker:Astrid Woollard ( Soschner ( Nateqi ( Life Science Invest ( Ventures ( ( you enjoy the podcast? Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers in the Q&A. The best questions will be featured in the podcast. Do you like this idea? Join today: the show (
Viral threats to humankind like the Coronavirus need scientists from all over the world collaborating to solve the problem. People like Saara Inkinen support scientists and universities to transfer their inventions to companies who turn science into products. These products help patients to overcome illnesses and stay healthy. In this episode you will get some information how Saara helps in that area.More information:Nordic Catalyst ( ( the show (
These days there is a lot of discussion about the development of diagnostics, therapeutics, and vaccines against the Coronavirus and it´s disease COVID 19. Viruses are one threat to the health of human beings. Bacteria is another one. Traditionally, bacterial infections are treated with antibiotics. Recently, some bacteria have developed antibiotic resistance.The WHO describes that Antibiotic resistance is one of the biggest threats to global health, food security, and development today. ( Phagomed ( is developing a novel approach to treat bacterial infections without antibiotics. How that works, the challenges a company has to face during the development of novel drugs, and why not all viruses are evil, you will hear in this episode.More information: you want to learn more about life science?Join exclusive future webinars and member-only events: Become a member of the LSG2G Network.Join today: the show (
Download from Google Play
Download from App Store